While the drop in Ultragenyx stock certainly provides a lower entry point for new investors, the more prudent choice right ...

Large pharmaceutical companies are entering a period of renewed relevance as therapeutic innovation accelerates, particularly ...

RedChip Companies will air interviews with Processa Pharmaceuticals, Inc. (Nasdaq:PCSA) and 60 Degrees Pharmaceuticals, Inc. ...

Shares of Agios Pharmaceuticals jumped nearly 16% on Wednesday after the U.S. Food and Drug Administration approved the ...

Discover why pharma sector leaders and AI innovation may drive the S&P 500 to 9,000 by 2026. Explore top stocks, growth ...

The market for weight-loss drug is expected to expand to more than $150 billion in revenue by the early 2030s, thanks to the ...

For most drugmakers, the US is the largest single market. Prices there are often close to three times higher than in other ...

Several Indian companies are preparing to launch generic versions of GLP-1 category drug Semaglutide in India ...

Ultragenyx Pharmaceutical and Mereo BioPharma said their two Phase 3 trials for setrusumab to treat rare bone disorder osteogenesis imperfecta, didn't meet their main goal of reducing fracture rates.

Royalty Pharma (RPRX) announced that it has acquired the final portion of PTC Therapeutics’ remaining royalty on Roche’s (RHHBY) Evrysdi for $240M ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the AI stocks under $20 to buy now. On December 8, Recursion ...

What defined pharma in 2025? Contract Pharma’s most‑viewed breaking news offers insights. Here’s your yearly recap—the most ...